Premium
News on infantile haemangioma. Part 2: therapy and evaluation
Author(s) -
Saerens J.,
De Leye H.,
Janmohamed S. R.
Publication year - 2021
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14537
Subject(s) - medicine , clinical practice , quality of life (healthcare) , propranolol , intensive care medicine , mechanism (biology) , pediatrics , medical physics , physical therapy , nursing , philosophy , epistemology
Summary Infantile haemangioma (IH) is the most frequently occurring tumour of childhood. While benign, in more than half of the cases, less or more severe sequelae can be observed. In Part 1 of this review, we discussed the clinical course and pathomechanism of IHs. In Part 2 of this state‐of‐the‐art review, we will discuss the current management of IH and focus on the working mechanism of β‐blockers in IHs. Furthermore, we will discuss options for the evaluation of patients and their families (quality of life and family burden), as well as for the evaluation of IHs by healthcare providers, such as assessments of activity and severity. This review will update the reader on the working mechanism of propranolol in IHs and offer an oversight of tools (questionnaires and scoring systems) that can be used in clinical practice or for research.